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 ABSTRACT 
 
Question: Increasing evidence supports the use of embolization to treat pulmonary 
arteriovenous malformations (AVMs).  Most pulmonary AVM patients have hereditary 
haemorrhagic telangiectasia (HHT), a condition that may be associated with pulmonary 
hypertension.  We tested whether PAVM embolization increases pulmonary artery pressure 
(PAP) in patients without baseline severe pulmonary hypertension. 
 
Methods: PAP were measured at the time of PAVM embolization in 143 individuals, 131 (92%) 
of whom had underlying HHT. Angiography/embolization was not performed in four 
individuals with severe pulmonary hypertension, whose systemic arterial oxygen saturation 
exceeded levels usually associated with dyspnoea in PAVM patients. 
 
Results: In 143 patients undergoing PAVM embolization, PAP was significantly correlated 
with age, with the most significant increase occurring in the upper quartile (age >58yr).  In 43 
patients with repeated measurements, there was no significant increase in PAP as a result of 
embolization.  In half, embolization led to a fall in PAP.  The maximum rise in PAP mean was 
8mmHg:  Test balloon occlusion was performed in one of these individuals, and did not predict 
the subsequent rise in PAP following definitive embolization of the pulmonary AVMs. 
 
Conclusions:  In this series which excluded patients with severe pulmonary hypertension, PAP 
was not increased significantly by PAVM embolization.   
 
 
Key words: brain abscess, hypoxaemia, nose bleeds, right to left shunt, oxygen saturation, 
stroke,  
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INTRODUCTION 
 
Does embolization of pulmonary arteriovenous malformations (AVMs) precipitate pulmonary 
hypertension (PH)? 
 
The reason this question is important is that for individuals with pulmonary AVMs, 
embolization is an effective means of reducing lifetime risks of paradoxical embolic stroke and 
brain abscess [1, 2],  improving oxygenation [3-17], and treating pulmonary AVM-related 
haemoptysis [16, 18, 19].  Conversely, embolization may be expected to elevate pulmonary 
artery pressure (PAP), since pulmonary AVMs are abnormal dilated vessels between 
pulmonary arteries and veins that provide low resistance pathways for pulmonary blood flow 
[20].  
The question of whether pulmonary AVM embolization increases PAP is particularly pertinant 
since most individuals with pulmonary AVMs have underlying hereditary haemorrhagic 
telangiectasia (HHT).  Typically recognised by nose bleeds, mucocutaneous telangiectasia and 
visceral AVMs [21], HHT may be associated with pulmonary hypertension (PH) [9, 22-30].  
The secondary causes of PH in HHT are diverse, as in the normal population [31], but PH 
particularly occurs either as a true pulmonary arterial hypertension (PAH) phenotype [9, 22, 
28-30], or in the context of high output cardiac failure secondary to hepatic AVMs, when PH 
may be reversible after hepatic AVM treatment [32].  The frequencies of PAH and hepatic 
AVMs differ with HHT genotype:  HHT is caused by mutations in at least five genes including 
endoglin (HHT type 1) and ALK-1 (HHT type 2), with pulmonary AVMs most common in 
HHT type 1 [33].  PAH phenotypes are more common in HHT type 2 [22, 28, 29] than HHT 
type 1 [30]. Hepatic AVMs are also more  frequent in HHT type 2 [33].   
Of more than 700 reported pulmonary AVM embolizations reported [1-18, 34-42], data on PAP 
measurements pre and post embolization are scarce  [9, 11, 17, 32].  In three of the four 
reported cases [9, 17, 32], each selected from larger series, PAP increased post embolization, 
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while in the fourth [11] it was unchanged.  There is also a report of worsening PH after surgical 
resection of a pulmonary AVM [43]. 
We have previously reported that in our population of pulmonary AVM patients, 92% of whom 
had HHT, the overall prevalence of pulmonary hypertension is low [44]. We hypothesised that 
in contrast to the limited data in the literature, pulmonary AVM embolization would not 
increase PAP.  Here we report the results of a retrospective study in the series of pulmonary 
AVM patients reported recently [2], performed to determine whether pulmonary AVM 
embolization affected pulmonary artery pressure, and whether it may be safe to extend our 
embolization practice to individuals with severe PH.    
 
METHODS 
Study population 
All studies were ethically approved by the Hammersmith, Queen Charlotte’s, Chelsea, and 
Acton Hospital Research Ethics Committee (LREC 00/5764), and performed as part of routine 
clinical management of individuals with pulmonary AVMs.  
 
SaO2 were measured as previously described [2, 4, 45].  For SaO2 values reported here, 
recordings were made every 60 seconds for 10 minutes standing, since SaO2 in the erect 
posture correlates better with right to left shunt [45].  All patients with pulmonary AVMs of a 
size amenable to embolization treatment underwent pulmonary angiography with a view to 
embolization, unless there was a major medical contraindication.  In view of theoretical 
concerns, angiography/embolization was not considered for four women referred to the service 
with severe pulmonary hypertension and well preserved oxygen saturations.  Pulmonary 
angiography was performed as previously described [4] in unpremedicated, conscious patients 
who had not been fluid-restricted pre-procedure.  Systolic, diastolic and mean PAP were 
recorded routinely prior to contrast injection via a multi-sidehole catheter (Grollman pigtail 
catheter (William Cook Europe, Bjaeverskov, Denmark)).  Measurements were repeated 
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immediately after embolization in the subgroup of individuals with higher PAP.  In the 
majority of patients, only a single angiography/embolization session was required [2]. 
 
Statistics 
 
Statistical analyses were performed using Prism 4 and Instat (Graph Pad Inc). For SaO2, the last 
four minutes readings for erect postures were entered as replicate data for each of the pre and 
post embolization data. Quartile group data were incorporated from the full series of 219 
pulmonary AVM patients, as reported in reference [2]. 
 
Age was expected to influence PAP, since catheterisation data at rest in two groups of healthy 
individuals (17 aged 16-28yr [46]; 15 aged 61-83 yr [47]) demonstrated significantly higher 
PAP systolic (mean 24.47 vs 19.94, p=0.003, Mann Whitney) and PAP mean (mean 16.13 vs 
13.65, p=0.026) in the older group. This has also been supported by more recent 
echocardiography data [48].  In our series, associations of PAP measurements with age were 
performed using Spearman rank analyses and linear regression.  The patients were also 
stratified into age-quartile groups, and interquartile differences analysed by one way analysis of 
variance (ANOVA) with post test correction for linear trend.   
 
In order to test whether PAP was elevated following embolization of pulmonary AVMs, PAP 
measurements recorded pre-embolization were studied in all patients with at least two PAP 
measurements.  39 pairs of consecutive PAP measurements recorded at the outset of at least 
two embolization sessions were available from 35 patients.  In addition, nine pairs of PAP 
measurements recorded pre and post embolization in the same session were available for eight 
patients with pre-existing mild to moderate pulmonary hypertension, in whom the repeat 
measurements during the same procedure had been justified as part of their clinical 
management.   To test the null hypothesis that embolization of pulmonary AVMs does not 
increase PAP, measurements pre and post embolization, and pre and age-adjusted post 
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embolization measurements, were analysed by two tailed paired t-test, and significance 
assessed at false discovery rate (FDR)=0.05 level [49].   
 
 
RESULTS 
 
Patient populations 
Patient ages ranged from 8 to 78yr at the time of embolization (Figure 1a).  In patients 
undergoing embolization, baseline SaO2 erect ranged from 73 to 98%, with a median value of 
93% as in the full population reported in reference [2] (Figure 1b).  For the four individuals 
who did not undergo embolization due to severe pre-existing PH, SaO2 (erect) was in the upper 
two quartiles of the full pulmonary AVM population, at levels for which the majority of 
individuals with did not experience dyspnoea [2] (Figure 1b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Baseline characteristics of study population 
Comparison of a) age, b) baseline SaO2 (erect), and c) PAP mean for the 143 patients undergoing embolization 
(plain symbols), and the four patients not offered embolization (ringed symbols).  For b), † symptomatic dyspnoea, 
and quartile groups are as reported for the 219 pulmonary AVM patients in reference [2].  d) Age-dependent 
increase in PAP mean in 143 patients with pulmonary AVMs.   
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Baseline PAP measurements (PAP systolic, diastolic and mean) varied widely as illustrated in 
Table 1a and Figure 1c.  The distribution of the embolized patients was skewed (Figure 1c), but 
nevertheless, the four patients who were not offered embolization represented significant 
outliers.  Further details of their haemodynamic variables are presented in Table 1b. 
 
Table 1:  Pulmonary haemodynamic variables in pulmonary AVM patients  
 
 
a: 143 patients  undergoing embolization of pulmonary AVMs 
 
PAP (mmHg) Median (Q1, Q3) Mean (range) Normal range [50]  
PAP systolic  23 (19-27) 23.6 (13-60) 13-26 
PAP diastolic 7 (5-9) 7.2 (0-30) 6-16 
PAP mean 13 (11-16) 13.5 (6-45) 7-19 
 
b: Four PH patients not undergoing pulmonary AVM embolization 
 
 
PH 
Case 
 
Age 
 
SaO2 
erect 
(%) 
 
RAP 
 
RVEDP 
 
PAP 
sys 
 
PAP 
ds 
 
PAP 
mean 
 
PC 
Wedge 
† 
 
CO 
(litres/ 
min) 
 
CI 
(litres/ 
min/m
2
) 
 
PVR 
(dyn sec/ 
cm
5
) ‡ 
#
144 64 100 12 10 74 21 41 17 7.0 4.0 272 
#
145
 
30 95 0 8 80 30 50 2 3.3 2.3 1160 
#
146 59 97.5 23 9 70 40 52 25 3.1 1.7 396 
#
147 53 92 12 9 55 38 40 18 7.8 4.6 274 
 
Legend:  Q1, Q3: interquartile range. RAP, right atrial pressure; RVEDP, right ventricular end diastolic pressure; 
sys, systolic; ds, diastolic; CO, cardiac output; CI, cardiac index; PVR, pulmonary vascular resistance. Normal 
ranges [50]: † 5-13mmHg, ‡  11-99 dyn  s/cm5. Note the variety of PH phenotypes in this population: Case #144 
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has post capillary PH; case 
#
145 has a PAH profile, and the other two cases display a mixed profile.  High output 
cardiac failure secondary to hepatic AVMs was present in cases 
#
144 and
#
146. 
 
 
Univariate analysis of first recorded PAP measurements in the 143 embolized patients indicated 
that all three PAP measurements were influenced by age.  For age and PAP mean, the 
Spearman r correlation was 0.33 (95% confidence intervals 0.17, 0.47; p<0.0001), and PAP 
mean could be described by the equation PAP mean = 9.88 + 0.107 *[age], r
2
 =12.33%, 
p<0.0001.  One way analysis of variance (ANOVA) indicated significant differences in PAP 
between age-quartile groups (Figure 1d). Post-test analysis confirmed a linear trend (p<0.0001), 
with significant increases occurring between the third (45-58yr) and upper (>58 yr) age 
quartiles (Figure 1d).  
 
 
Effect of embolization 
 
In order to test whether PAP was elevated following embolization of pulmonary AVMs, PAP 
measurements recorded pre-embolization were studied in all 43 patients for whom post 
embolization measurements were also available, either from consecutive sessions (35 patients), 
or from the same embolization session (8 patients).  
 
For the 35 patients in whom measurements were made prior to consecutive embolization 
sessions, SaO2 increased in all except one of the patients following embolization (p<0.0001, 
Figure 2a).  In contrast, there was no significant change in PAP as a result of embolization 
(Figure 2b). There was a trend towards higher PAP post embolization, but this was in part 
accounted for by increased patient age, as measurements were recorded at a mean interval of 
19.9 (range 2-121) months.  
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Figure 2: Effects of pulmonary AVM embolization  
a)  SaO2 (erect) and b) PAP mean recorded at consecutive embolisation sessions in 35 patients. In b), age adjusted 
figures were calculated by PAP mean = 9.88 + 0.107 *[age] as defined in the population (see text).    Overall p 
values did not reach significance at FDR=0.05 level [49].  
 
 
 
Recognising that the pooled groups may have masked individual changes, individual PAP 
responses were examined in a subgroup of 15 patients with PAP mean in the upper quartile.  In 
this small group, embolization resulted in a highly significant improvement in SaO2 (p<0.0001, 
Figure 3a).  In contrast, PAP measurements recorded at a mean interval of 26 (range 13-80) 
months demonstrated no consistent trend, and no significant difference between pre and post 
embolization measurements (p=0.76, Figure 3b).  Comparable findings were observed with 
PAP systolic and PAP diastolic (data not shown). 
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These measurements addressed whether embolization led to a sustained change in PAP.  In 
order to explore whether there were any acute changes in PAP, nine pairs of PAP 
measurements recorded pre and post embolization in the same session were examined.  
Embolization resulted in a consistent and highly significant improvement in SaO2 (p=0.0039, 
Figure 3c).  Again PAP responses to pulmonary AVM embolization varied between individuals.  
In half of all patients, post embolization PAP mean was lower than prior to embolization, and 
overall there was no significant difference as a result of embolization (p=0.93, (Figure 3d). 
Comparable findings were observed with PAP systolic and PAP diastolic (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Individual patient details 
a) SaO2 (erect) and b) PAP mean recorded at consecutive embolisation sessions in subgroup of 15 patients with 
pre-existing elevated PAP mean (≥16mmHg).  c) SaO2 (erect) and d) PAP mean recorded pre and post 
embolisation at same session in 8 patients with pre-existing elevated PAP mean (≥16mmHg). The two 
measurements for the patient with test balloon occlusion reported in Table 2 are illustrated by dotted lines. 
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While overall, there were no significant increase in PAP as a result of embolization, within 
both groups there were occasional individuals in whom PAP did increase, by up to 8mmHg 
between consecutive sessions, and up to 4mmHg during the same session.  It may be helpful to 
be able to identify these rare individuals prior to embolization.  Others have suggested test 
occlusion of the pulmonary AVM before definite embolization [32].  This technique was tried 
for one patient early in the series. Balloon occlusion  increased SaO2 to a similar degree as 
eventual complete embolization (Table 2). This test occlusion did not significantly increase 
PAP whereas PAP were significantly higher following maximal embolization.  
  
 
Table 2:
 
Comparison of balloon test occlusion and pulmonary AVM embolization 
 
Date Day 0 
pre 
Day 0 
(post 
balloon) 
Day 8  
pre 
Session 1 
Day 8 post 
PAVM emb.   
Day 169 
pre 
Session 2 
Day 169 post 
PAVM emb.  
Change 
post 
balloon 
 
Change post  
complete emb. 
SaO2 (%) 67 85 69 80 81 89 +18 +22 
PAP sys (mmHg) 47 50 54 60 57 63 +3 +16 
PAP d/s (mmHg) 0 0 24 32 27 35   0 +35 
PAP mean (mmHg) 22 25 34 41 36 44 +3 +22 
 
Legend: Emb. Embolization.  Test occlusion (stable for 5 minutes), and subsequent data following two separate 
PAVM embolization sessions in a 65 year old man with pulmonary hypertension secondary to left ventricular 
disease.  The embolization sessions reduced the right to left shunt from 18% to 13.3% (session 1), then to 
undetectable levels (session 2).  In session 1, embolization was curtailed due to the rise in PAP. 
 
 
 
DISCUSSION 
 
 
The key finding of this study was that embolization of pulmonary AVMs did not lead to a 
consistent increase in resting PAP in a series which excluded individuals with severe 
pulmonary arterial hypertension. 
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The strengths of the study included the relatively large patient group, correction for age which 
could have been an important confounding variable in assessments over consecutive 
embolization sessions, and strong evidence of embolization efficacy.  Weaknesses include the 
retrospective nature of the study, and reliance on measurements performed for clinical purposes 
such that pulmonary vascular resistance (PVR) measurements, and same-session repeat 
measurements following embolization were not available for the majority of patients.  In 
addition, the study was only powered to address consistent changes pre and post embolization.    
 
Within the study limitations, in our series, embolization of pulmonary AVMs did not generally 
increase PAP, even in the setting of mild-to-moderate pre-existing pulmonary hypertension. No 
patient developed clinical PAH (i.e. right-heart failure) after embolization in this series 
 
We were surprised by the significant fall in PAP in one patient with pre-existing pulmonary 
hypertension attributed to left ventricular disease.  We were also initially surprised to see that 
embolization did not lead to a consistent increase in PAP in other patients, since effective 
embolization occludes vessels that provide a lower resistance to flow than the rest of the 
pulmonary vasculature [20].  None of the patients illustrated in Figure 3 were known to have 
hepatic AVMs, and this may explain the differences between our results and those of others.  
Importantly however, noting that embolization leads to a reduction in cardiac output [11, 17], 
our data suggest that the fall in cardiac output can have a greater effect on PVR than occlusion 
of individual pulmonary AVMs.   
 
While our data indicate that pulmonary AVM embolization does not necessarily lead to 
elevated PAP, PAP did rise in occasional individuals, rises which in this series, were not 
predicted by test balloon occlusion pre embolization.   It is important to recognise that in the 
setting of severe PAH and HHT-associated hepatic AVMs, there are reports that embolization 
of pulmonary AVMs may precipitate fatal increase in PAP [32]. Furthermore, in addition to the 
previously reported cases, clinical PAH did develop in another patient in our series [2] in the 
years following pulmonary AVM resection and embolization at another institution.   
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Our interpretation of these considerations, and our observations from the series reported here 
and elsewhere [2], is that for patients with pre-existing severe pulmonary arterial hypertension, 
the risks of pulmonary AVM embolization outweigh potential benefits:  The main indications 
for pulmonary AVM embolization are to reduce the risk of paradoxical embolic stroke, and, for 
individuals with hypoxaemia, to improve dyspnoea, and exercise tolerance.   We have recently 
shown that the risk of paradoxical embolic stroke is substantially lower in individuals with 
higher PAP [2].  Furthermore, the data reported here serve as a reminder that pulmonary AVMs 
generally result in symptomatic dyspnoea only when resting SaO2 are <80%, suggesting 
perhaps that symptomatic relief should not be expected for patients with pulmonary 
hypertension and SaO2 >90% as was the case in all four excluded patients in our series.  In our 
experience, the most difficult judgements relate to individuals with elevated pulmonary artery 
pressure and major haemoptysis, a consideration that was not required for the four individuals 
with PH in this series.  
 
 
In summary, these data are a useful adjunct to case reports indicating increased PAP post 
embolization, and indicate that embolization may be undertaken with caution in the presence of 
pre-existing mild to moderate pulmonary hypertension in selected individuals.  
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